OROXCELL
Oroxcell is a drug discovery and development company identifying new generation of chemical entities dedicated to pain treatment.
- Stage Product In Development
- Industry Biotechnology
- Location Romainville, IDF, France
- Currency EUR
- Founded July 2004
- Employees 25
- Website oroxcell.com
Company Summary
Primary clinical indications of Oroxcell compounds are visceral, chronic, neuropathic and osteoarthritic pain. ORC056, lead candidate, shows an excellent safety profile and a strong analgesic effect in all animal models tested. The compounds benefit from a strong IP and have low cost of synthesis (5 chemical steps). Oroxcell is looking for 1.5 M€ to pursue preclinical development of ORC056 up to an indentified deal with a major Pharma leader.
Team
-
Jean PachotPresident and CSO
- 24 years experience in Pharma industry in various managing positions,
- Responsible for the creation of the Investigation of Drug Transport unit,
- Participation in the research and development of Ketek®, Rulid®, Mifegyne ®, Odrik® HMR1297, HMR1404, HMR3270, HMR3432 and contribution to more than 18 R&D programs. -
Christophe DiniCOO
- 20 years experience in Pharma industry as Group Leader in Medicinal Chemistry, Project Leader in preclinical development…,
- Responsible for several research programs, in nutrition, oncology and infectious diseases, and recognized as expert in the field of antibacterial research,
- Author of several publications, patents, reviews and book chapters.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.